What are the learnings from the one-year VANTAGE TAVI outcomes in low/intermediate-risk patients?

Birgid Gonska, Henryk Dreger and Christophe Saint Etienne review the one-year results of the VANTAGE trial evaluating the Navitor TAVI device in younger, low- and intermediate-risk patients, showing very favourable outcomes with a low composite rate of mortality and disabling stroke (2.6%), very good valve performance, stable low gradients, and no moderate or severe paravalvular leak (PVL). A key focus is the importance of lifetime management in younger patients, with encouraging durability data from earlier studies showing stable valve function at 5 years without dysfunction or PVL. The Navitor device is seen as a valuable addition to the TAVI toolkit, offering advantages such as good coronary access and suitability for future reinterventions, making it well-suited for individualised, patient-tailored treatment strategies.

This interview was filmed at EuroPCR 2026: see more videos here.